




JFW

PATENT
Docket No. 391442006300

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on September 21, 2004.


Rhea Amid

Rhea Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Gary BRIDGER et al.

Serial No.: 10/823,494

Filing Date: April 12, 2004

For: CXCR4 CHEMOKINE RECEPTOR
BINDING COMPOUNDS

Examiner: Not Yet Assigned

Group Art Unit: 1614

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. §1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are not submitted. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of __ is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does


not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **391442006300**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: September 21, 2004

Respectfully submitted,

By:



Emily C. Tongco
Registration No. 46,473

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 314-5413
Facsimile: (858) 720-5125



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/823,494
		Filing Date	April 12, 2004
		First Named Inventor	Gary BRIDGER
		Art Unit	1614
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	10	Attorney Docket Number	391442006300

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Form PTO-1449 (3 pages + duplicate) 67 References Return Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement (3 pages)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

CUSTOMER NO. 25225

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP Emily C. Tongco - 46,473
Signature	
Date	September 21, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 9-21-04

Signature: (Rhea Amid)

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 391442006300 Application Number: 10/823,494

Applicant:

Gary BRIDGER et al.

Filing Date: April 12, 2004

Group Art Unit: 1614

Mailing Date September 21, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	06/1991	5,021,409	Murrer et al.	514	183	
	2.	12/1996	5,583,131	Bridger et al.	514	183	
	3.	12/1997	5,698,546	Bridger et al.	514	183	
	4.	10/1998	5,817,807	Bridger et al.	540	474	
	5.	12/1999	6,001,826	Murrer et al.	514	183	
	6.	04/2002	6,365,583	MacFarland et al.	514	183	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	7.	12/2000	WO 00/02870	WIPO			
	8.	09/2000	WO 00/56729	WIPO			
	9.	03/2002	WO 02/22599	WIPO			
	10.	03/2002	WO 02/22600	WIPO			
	11.	05/2002	WO 02/34745	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	12.	Abi-Younes, et al., Circ. Res. (2000) 86:131-138
	13.	Alkhatib, et al., Science (1996) 272:1955-1958
	14.	Arai, et al., Eur. J. Haematol. (2000) 64:323-332
	15.	Arenberg, et al., J. Leukocyte Biol. (1997) 62:554-562
	16.	Aiuti, et al., J. Exp. Med. (1997) 185:111-120
	17.	Blaak, et al., Proc. Natl. Acad. Sci. (2000) 97:1269-1274
	18.	Blanco, et al., Antimicrobial Agents and Chemother. (2000) 44:51-56
	19.	Bleul, et al., J. Exp. Med. (1998) 187:753-762
	20.	Bleul, et al., Nature (1996) 382:829-833

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number: 391442006300	Application Number: 10/823,494
		Applicant: Gary BRIDGER et al.	
		Filing Date: April 12, 2004	Group Art Unit: 1614
		Mailing Date September 21, 2004	

21.	Bradstock, et al., Leukemia (2000) 14:882-888
22.	Bridger, et al., J. Med. Chem. (1999) 42:3971-3981
23.	Burger, et al., Blood (1999) 94:3658-3667
24.	Carroll, et al., Science (1997) 276:273-276
25.	Cocchi, et al., Science (1995) 270:1811-1815
26.	Connor, J. Virol. (1994) 68:4400-4408
27.	Deng, et al., Nature (1996) 381:661-666
28.	Donzella, et al., Nature Medicine (1998) 4:72-77
29.	Dragic, et al., Nature (1996) 381:667-673
30.	Egberink, et al., J. Virol. (1999) 73:6346-6352
31.	Eitner, et al., Transplantation (1998) 66:1551-1557
32.	Fedyk, et al., J. Leukocyte Biol. (1999) 66:667-673
33.	Feng, et al., Science (1996) 272:872-877
34.	Gonzalo, et al., J. Immunol. (2000) 165:499-50
35.	Gupta, et al., J. Biolog. Chem. (1998) 273(7):4282-4287
36.	Ishii, et al., J. Immunol. (1999) 163:3612-3620
37.	Lataillade, et al., Blood (2000) 95:756-768
38.	Liu, et al., Cell (1996) 86:367-377
39.	Ma, et al., Immunity (1999) 10:463-471
40.	Maekawa, et al., Internal Medicine (2000) 39:90-100
41.	Michael, et al., Nature Med. (1997) 3:338-340
42.	Michael, et al., J. Virol. (1998) 72:6040-6047
43.	Miedema, et al., Immune. Rev. (1994) 140:35-72
44.	Moore, et al., J. Invest. Med. (1998) 46:113-120
45.	Moore, et al., Trends Cardiovasc. Med. (1998) 8:51-58
46.	Murdoch, et al., (2000) Blood 95:3032-3043
47.	Nagasawa, et al., Nature (1996) 382:635-638
48.	Nagase, J. Immunol. (2000) 164:5935-5943
49.	Nanki, et al., J. Immunol. (2000) 164:5010-5014
50.	Oberlin, et al., Nature (1996) 382:833-835
51.	O'Brien, et al., Lancet (1997) 349:1219

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number: 391442006300	Application Number: 10/823,494
		Applicant: Gary BRIDGER et al.	
		Filing Date: April 12, 2004	Group Art Unit: 1614
		Mailing Date September 21, 2004	

52.	Peled, et al., Science (1999) 283:845-848
53.	Peled, et al., Blood (2000) 95:3289-3296
54.	Ponath, Exp. Opin. Invest. Drugs (1998) 7:1-18
55.	Rana, et al., J. Virol. (1997) 71:3219-3227
56.	Salcedo, et al., Am. J. Pathol. (1999) 154:1125-1135
57.	Samson, et al., Nature (1996) 382:722-725
58.	Schols, et al., J. Exp. Med. (1997) 186:1383-1388
59.	Schols, et al., Antiviral Research (1997) 35:147-156
60.	Schuitemaker, et al., J. Virol. (1992) 66:1354-1360
61.	Seghal, et al., J. Surg. Oncol. (1998) 69:99-104
62.	Simmons, et al. J. Virol. (1996) 70:8355-8360
63.	Simmons, et al., J. Virol. (1988) 72:8453-8457
64.	Tachibana, et al., Nature (1998) 393:591-594
65.	Tersmette, et al., J. Virol. (1988) 62:2026-2032
66.	Theodorou, et al., Lancet (1997) 349:1219-1220
67.	Viardot, et al., Ann. Hematol. (1998) 77:193-197
68.	Wyatt, et al., Science (1998) 280:1884-1888
69.	Xia, et al., J. Neurovirology (1999) 5:32-41
70.	Yssel, et al., Clinical and Experimental Allergy (1998) 28:104-109
71.	Zhang, et al., AIDS Res. Hum. Retroviruses (1997) 13:1357-1366
72.	Zhang, et al., J. Virol. (1998) 72:9307-9312
73.	Zhang, et al., J. Virol. (1999) 73:3443-3448

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	